Document Detail


Cardioprotection by ivabradine through heart rate reduction and beyond.
MedLine Citation:
PMID:  21821529     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The present review summarizes the experimental and clinical evidence for the anti-ischemic action of the selective bradycardic agent ivabradine. Improvements in myocardial blood flow and contractile function during experimental myocardial ischemia and the clinical anti-anginal effect are largely mediated by heart rate reduction. However, a significant reduction in infarct size by ivabradine persists in the absence of heart rate reduction, and such protection can also be recruited when ivabradine is given only during early reperfusion. The mechanisms for such pleiotropic action of ivabradine remain to be resolved.
Authors:
Gerd Heusch; Andreas Skyschally; Rainer Schulz
Related Documents :
3544969 - Salvage of ischemic myocardium by cls 2210 in the dog: a preliminary double-blind study.
22158969 - Myocardial atgl overexpression decreases the reliance on fatty acid oxidation and prote...
22185559 - Systematic review: comparative effectiveness of adjunctive devices in patients with st-...
22567299 - The unusual circulation of the newt heart after ventricular injury and its implications...
8326529 - Improved myocardial protection by antegrade perfusion in combination with coronary sinu...
22668069 - Mitochondrial pathways, permeability transition pore and redox signaling in cardioprote...
9036749 - Comparison of patients with either < 70% diameter narrowing or > or = 70% narrowing of ...
23108779 - Coronary ct angiography and high-risk plaque morphology.
8534689 - Peritoneal transport evaluation in peritonitis: comparison between methods.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  16     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  281-4     Citation Subset:  IM    
Affiliation:
1Institut für Pathophysiologie, Universitätsklinikum Essen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is It Time to Translate Ischemic Preconditioning's Mechanism of Cardioprotection into Clinical Pract...
Next Document:  New frontiers in myocardial protection: a systems biology approach.